The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer
Open accessAbstract
IMPORTANCE: Immune dysfunction underlies the pathogenesis of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Immunosuppressive therapy is the standard of care for these diseases. Both immune dysfunction and therapy-related immunosuppression can inhibit cancer-related immune surveillance in this population. Drug-induced immunosuppression is a risk factor for nonmelanoma skin cancer (NMSC), particularly squamous cell tumors. For patients with a history of NMSC, data are limited on the effect of these drugs on the risk of additional NMSCs. OBJECTIVE: To determine the relative hazard of a second NMSC in patients with RA or IBD who use methotrexate, anti-tumor necrosis factor (anti-TNF) therapy, or thiopurines after an initial NMSC. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study, we studied 9460 individuals with RA or IBD enrolled in Medicare from January 1, 2006, through December 31, 2012. EXPOSURES: Exposure to methotrexate, thiopurines, anti-TNFs, sulfasalazine, hydroxychloroquine, abatacept, or rituximab after the incident NMSC surgery. MAIN OUTCOMES AND MEASURES: A second NMSC occurring 1 year or more after the incident NMSC using Cox proportional hazards regression models. RESULTS: Among 9460 individuals (6841 with RA and 2788 with IBD), the incidence rate of a second NMSC per 1000 person-years was 58.2 (95% CI, 54.5-62.1) and 58.9 (95% CI, 53.2-65.2) in patients with RA and IBD, respectively. Among patients with RA, methotrexate used in conjunction with other medications was associated with an increased risk of a second NMSC (hazard ratio [HR], 1.60; 95% CI, 1.08-2.37). Adjusted for other medications, the risk of NMSC increased with 1 year or more of methotrexate use (HR, 1.24; 95% CI, 1.04-1.48). Compared with methotrexate alone, the addition of anti-TNF drugs was significantly associated with risk of NMSC (HR, 1.49; 95% CI, 1.03-2.16). Abatacept and rituximab were not associated with increased NMSC risk. The nonsignificant HRs for 1 year or more of thiopurine and anti-TNF use for IBD were 1.49 (95% CI, 0.98-2.27) and 1.36 (95% CI, 0.76-2.44), respectively. CONCLUSIONS AND RELEVANCE: Methotrexate use is associated with an increased risk of a second NMSC. Anti-TNF use may increase the risk of a second NMSC when used with methotrexate for RA. Further long-term studies are required before one can conclude that thiopurine and/or anti-TNF do not increase the risk of a second NMSC in patients with IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Abraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF-α Blockade with Nonbiologic DMARDs
Solomon, D. H., Curtis, J. R., Saag, K. G., Lii, J., Chen, L., Harrold, L. R., Herrinton, L. J., Graham, D. J., Kowal, M. K., Kuriya, B., et al. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.02.016 · Cited by 111
Self-citationUVA photosensitization of thiopurines and skin cancer in organ transplant recipients
Attard, N. R., & Karran, P. (2012) · Photochemical & Photobiological Sciences · doi:10.1039/c1pp05194f · Cited by 94 · cited 1×
“Exposure Definition The following medications were considered exposures of interest: (1) methotrexate, (2) thiopurines (azathioprine or 6-mercaptopurine), (3) anti-TNFs (infliximab, adalimumab, certolizumab, golimumab, or etanercept), (4) leflunomide, (5) tocilizumab, (6) abatacept, (7) rituximab, and (8) sulfasalazin…”
Cited by
ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
Gordon, H., Biancone, L., Fiorino, G., Katsanos, K. H., Kopylov, U., Al Sulais, E., Axelrad, J. E., Balendran, K., Burisch, J., de Ridder, L., et al. (2023) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac187 · Cited by 317
Nash, P., Kerschbaumer, A., Dörner, T., Dougados, M., Fleischmann, R. M., Geissler, K., McInnes, I., Pope, J. E., van der Heijde, D., Stoffer-Marx, M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218398 · Cited by 299
Metadata
- Authors
- Scott, F. I., Mamtani, R., Brensinger, C. M., Haynes, K., Chiesa-Fuxench, Z. C., Zhang, J., Chen, L., Xie, F., Yun, H., Osterman, M. T., Beukelman, T., Margolis, D. J., Curtis, J. R., & Lewis, J. D.
- Venue
- JAMA Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-02-01
- Volume
- 152
- Issue
- 2
- Pages
- 164
- ISSN
- 2168-6068 (ISSN-L)
- OpenAlex
- W1892676932
- Cited by
- 180
- References
- 6
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. https://app.cochat.ai/papers/10.1001/jamadermatol.2015.3029
- The paper
- Scott, F. I., Mamtani, R., Brensinger, C. M., Haynes, K., Chiesa-Fuxench, Z. C., Zhang, J., Chen, L., Xie, F., Yun, H., Osterman, M. T., Beukelman, T., Margolis, D. J., Curtis, J. R., & Lewis, J. D. (2016). Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2015.3029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.